Search
Alnylam Pharmaceuticals Inc
ALNYAdd to Watchlist
232.680USD
+8.150+3.63%
Close 10-09 16:00（ET）
31.07BMarket Cap
56.90P/E TTM
Alnylam Pharmaceuticals Inc (ALNY) Stock Price Target & Forecast
Analyst Rating
Based on 30 analysts giving stock ratings to Alnylam Pharmaceuticals Inc in the past month.
Buy
5 Strong Buy
18 Buy
7 Hold
0 Sell
0 Strong Sell
Target Price
371.409USD+65.50%
ALNY Analyst Recommendation Trends
In the current month, ALNY has received 18 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the last month is 371.409.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
5
5
5
5
6
6
6
6
18
18
17
17
17
16
16
16
7
7
8
8
7
8
8
9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30
30
30
30
30
30
30
31
ALNY Analyst Rating for Peer Comparison
Updated: Oct 10, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
8
16
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
2
0
31
Regeneron Pharmaceuticals Inc
REGN
6
15
10
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Financial Forecasting
Based on analysts' estimates, ALNY EPS is projected to reach 1.736 in FY2026Q3, following reported EPS of 1.231 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.12
0.96
1.55
1.74
1.87
Actual
1.41
1.55
1.23
--
--
Surprise
+25.41%
+61.09%
-20.81%
--
--
FAQs
What is Alnylam Pharmaceuticals Inc's expected revenue for the next quarter?
Alnylam Pharmaceuticals Inc's expected revenue is 1.44B.
What is Alnylam Pharmaceuticals Inc's price target?
Analysts forecast that Alnylam Pharmaceuticals Inc's price target is USD 371.02, with the highest forecast at USD 566.00 and the lowest forecast at USD 236.00.
How have Alnylam Pharmaceuticals IncALNY's recent earnings per share performed?
The market expectation was USD 1.23, while Alnylam Pharmaceuticals IncALNY's earnings per share (EPS) for the previous quarter was USD 1.55. EPS for the next quarter is expected at USD 1.74.
What is the analyst rating for Alnylam Pharmaceuticals Inc?
Based on the ratings of Alnylam Pharmaceuticals Inc's stock from 30 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.